Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
Tegoprazan, a novel patented molecule indicated for acid-related gastrointestinal diseases, is launched in India under the brand name PCAB
AINU is set to accelerate its expansion footprint, enhance operational capabilities
The system is powered by advanced imaging innovations such as Amber-red Color Imaging, Triple Noise Reduction, and Extended Dynamic Range Image Processing
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
In 2023, Endox had revenues of approximately SEK 65 million
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
AHH will make an investment of Rs. 600 crore in the company through a mix of primary and secondary infusion
Subscribe To Our Newsletter & Stay Updated
